Jain Gaurav, Otto Mathew, Mohammed Abdul Mubeen Khan, Chadha Manpreet, Sahajpal Ajay
Aurora St. Luke's Medical Center Abdominal Transplant Program, Advocate Aurora Health, Milwaukee, WI.
J Patient Cent Res Rev. 2022 Jul 18;9(3):181-184. doi: 10.17294/2330-0698.1878. eCollection 2022 Summer.
Hepatocellular carcinoma (HCC) is primary hepatic malignancy with a high incidence of recurrence. The risk of recurrence directly correlates to patient's overall prognosis. Management of advanced HCC involves a combination of surgical resection, locoregional therapy, and systemic treatment. Distant metastases are rare, and intraventricular cardiac metastases are even more infrequent. This brief review details an illustrative case of cardiac metastasis after curative treatment of primary HCC and then summarizes the literature on risk factors, treatment options, and patient prognosis in the setting of distant metastases from HCC. Prognosis of metastasis to the heart is generally poor, and available evidence emphasizes the importance of maintaining regular posttreatment screening for metastases in patients with HCC. Given the variable presentation and high risk of recurrence, it is critical to have individualized multimodality treatment plans.
肝细胞癌（HCC）是一种复发率很高的原发性肝脏恶性肿瘤。复发风险与患者的总体预后直接相关。晚期HCC的治疗包括手术切除、局部区域治疗和全身治疗的联合应用。远处转移很少见，而心脏室内转移则更为罕见。本简要综述详细介绍了1例原发性HCC根治性治疗后发生心脏转移的病例，并总结了关于HCC远处转移的危险因素、治疗选择和患者预后的文献。心脏转移的预后通常较差，现有证据强调了对HCC患者进行定期治疗后转移筛查的重要性。鉴于临床表现的多样性和复发风险高，制定个体化的多模式治疗方案至关重要。
